Hikma launches new 503B Sterile Compounding Business
10 January 2022
Case Study, Corporate
Hikma Pharmaceuticals announces the launch of Hikma 503B – a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.
Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.